RIGL Stock Overview
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Rigel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.09 |
| 52 Week High | US$29.82 |
| 52 Week Low | US$7.48 |
| Beta | 1.22 |
| 1 Month Change | -34.37% |
| 3 Month Change | 25.11% |
| 1 Year Change | 22.07% |
| 3 Year Change | -39.82% |
| 5 Year Change | -17.84% |
| Change since IPO | -97.33% |
Recent News & Updates
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Dec 20
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08Recent updates
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Dec 20Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Oct 10Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Sep 25There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise
Jul 30Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Jul 24Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21Shareholder Returns
| RIGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.6% | -3.6% | -2.4% |
| 1Y | 22.1% | -2.7% | 23.3% |
Return vs Industry: RIGL exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: RIGL underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| RIGL volatility | |
|---|---|
| RIGL Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RIGL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RIGL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 147 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.
Rigel Pharmaceuticals, Inc. Fundamentals Summary
| RIGL fundamental statistics | |
|---|---|
| Market cap | US$301.04m |
| Earnings (TTM) | US$3.88m |
| Revenue (TTM) | US$157.37m |
77.6x
P/E Ratio1.9x
P/S RatioIs RIGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RIGL income statement (TTM) | |
|---|---|
| Revenue | US$157.37m |
| Cost of Revenue | US$37.58m |
| Gross Profit | US$119.79m |
| Other Expenses | US$115.91m |
| Earnings | US$3.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 76.12% |
| Net Profit Margin | 2.47% |
| Debt/Equity Ratio | -681.5% |
How did RIGL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rigel Pharmaceuticals, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| Clarence Powell | BMO Capital Markets Equity Research |
| James Birchenough | BMO Capital Markets Equity Research |